- Home
- PETZ vs AEON Comparison
PETZ vs AEON Comparison
Compare PETZ & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | AEON |
|---|---|---|
| Founded | 2002 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 13.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETZ | AEON |
|---|---|---|
| Price | $1.20 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | 4.9K | ★ 672.2K |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.18 |
| 52 Week High | $1.83 | $1.45 |
Technical Indicators
Market Signals| Indicator | PETZ | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 30.43 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.37 | $0.33 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.76 | 17.22 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.